Investment Management Software Enfusion Prices US$318.75 Million IPO

Accounts payable automation software Enfusion, Inc. (NYSE: ENFN) started publicly trading on the New York Stock Exchange today. The firm’s initial public offering is looking to raise US$318.75 million.

The offering will be conducted through the issuance of 18.75 million Class A common shares selling at US$17.00 per share. Out of this, around 3.43 million shares will be sold by the company’s existing stockholders while the remaining 15.32 million shares will be offered by the company itself.

The company granted the underwriters a 30-day over-allotment option to purchase additional 2.81 million common shares at the same IPO price. Morgan Stanley & Co. and Goldman Sachs & Co. are all acting as joint lead bookrunners for the said offering.

The firm also relayed that it intends to use the offering proceeds to purchase equity interests in its operating subsidiary Enfusion Ltd. which in turn will use the funds to repay indebtedness and pay IPO-related expenses.

The offering is expected to close on October 25, 2021, subject to customary closing conditions.

Enfusion is a cloud-based investment management software platform aimed at streamlining the investment process by tying the front, middle, and back-office functions. The firm is currently present in nine global offices partnering with 600+ investment managers.


Information for this briefing was found via Sedar and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

SSR Mining Walks Away From a World Class Gold-Copper Project

Why More Canadians Are Starting to Think About Leaving | Jesse Day

Instead of Waiting, This Gold Developer Went Bigger | Kenneth McLeod – Sonoro Gold

Recommended

Why This Gold Company Keeps Spinning Out Assets | John-Mark Staude – Riverside Resources

Silver at $75 and Why U.S. Silver Ounces Are Getting Hard to Find | Galen McNamara – Silver47

Related News

Biopharma Absci Prices US$200 Million IPO

Synthetic biology company Absci Corporation began trading on the Nasdaq Global Select Market today under...

Thursday, July 22, 2021, 12:43:00 PM

It’s Been A Painful Year For IPOs, Proceeds Are Down 93%

It hasn’t been a good year for companies going public  — uncertainty from mounting recession...

Monday, December 5, 2022, 03:06:00 PM

Cannabis SPAC Relativity Acquisition Prices US$125 Million IPO

Special purpose acquisition company Relativity Acquisition Corp. (Nasdaq: RACYU) started trading its securities on the...

Friday, February 11, 2022, 02:17:00 PM

Oncology Firm TransCode Therapeutics Looks To Raise US$25 Million In IPO

Oncology company TransCode Therapeutics, Inc. is set to begin publicly trading its equityon the Nasdaq...

Friday, July 9, 2021, 09:53:00 AM

SpaceX’s Prospectus Is Coming—and the Hype Is Already Ahead of the Numbers

SpaceX is about to file its public prospectus — the first time the world will...

Monday, May 18, 2026, 05:42:52 AM